Research map: Sex-Specific Safety Profiles of PI3K Inhibitors: A Real-World Pharmacovigilance Study Based on FAERS Database

Back to the article

Papers in this map

  1. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer · Fabrice André · 2019 · 2663 citations · Cited by this paper
  2. Mycotoxin Trends of Cannabis Compliance Testing in Cannabis Flower and Concentrates in the United States · 2026 · Related
  3. Sex differences in pharmacokinetics predict adverse drug reactions in women · Irving Zucker · 2020 · 813 citations · Cited by this paper
  4. Early-Onset Cannabis Use, Retinal Biomarkers, and Risk for Schizophrenia Preliminary Study · 2026 · Related
  5. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database · Jean‐Louis Montastruc · 2011 · 521 citations · Cited by this paper
  6. Novel Therapeutic Treatments in Perinatal Genetics Bridging Prenatal and Postnatal Care of Genetic Conditions · 2026 · Related
  7. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration · Michele Fusaroli · 2024 · 335 citations · Cited by this paper
  8. Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study · 2026 · Related
  9. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement · Michele Fusaroli · 2024 · 245 citations · Cited by this paper
  10. Implications of TLR4 Polymorphisms for Precision Therapeutics in Gram-negative Infections: An Ethnogeographic-Stratified Meta-Analysis · 2026 · Related
  11. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study · Linghui Zhou · 2019 · 207 citations · Cited by this paper
  12. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitors in NSCLC: Insights From Pharmacovigilance Data, a Retrospective Case-control Study, and Single-cell RNA Sequencing Dataset · 2026 · Related
  13. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer · Hope S. Rugo · 2020 · 196 citations · Cited by this paper
  14. Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research · 2026 · Related
  15. Development and safety of PI3K inhibitors in cancer · Miaomiao Yu · 2023 · 99 citations · Cited by this paper
  16. Benefits of Medical Cannabis in Patients With Pain Registered in the Minnesota Medical Cannabis Program · 2026 · Related
  17. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019 · Juliana Setyawan · 2021 · 90 citations · Cited by this paper
  18. A Simultaneous Assessment of Efficacy and Safety of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease · 2026 · Related
  19. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019 · Yiyi Yao · 2022 · 90 citations · Cited by this paper
  20. Comment on “Effect of Remimazolam or Propofol Combined With Esketamine on Anesthesia and Early Perioperative Neurocognitive Disorders in Patients Undergoing Thoracoscopic Partial Lung Resection: A Randomized Clinical Trial” · 2026 · Related
  21. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper · Antonio Cuneo · 2018 · 78 citations · Cited by this paper
  22. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma · Benjamin L. Lampson · 2017 · 76 citations · Cited by this paper
  23. A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database · Haiyan Yang · 2023 · 62 citations · Cited by this paper
  24. Sex Differences in Immune Responses to Infectious Diseases: The Role of Genetics, Hormones, and Aging · Pierluigi Rio · 2025 · 33 citations · Cited by this paper
  25. Biological sex differences in pharmacokinetics and adverse drug reactions · Ahmad Aljohmani · 2025 · 30 citations · Cited by this paper
  26. Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses · Jacopo Canzian · 2025 · 25 citations · Cited by this paper
  27. Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system · Zhiping Li · 2023 · 21 citations · Cited by this paper
  28. Caveats of Covariate Adjustment in Disproportionality Analysis for Best Practices · Yoshihiro Noguchi · 2024 · 19 citations · Cited by this paper
  29. Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases · Jingjing Wang · 2022 · 17 citations · Cited by this paper
  30. Adverse drug reaction signals mining comparison of amiodarone and dronedarone: a pharmacovigilance study based on FAERS · Ye Xu · 2024 · 15 citations · Cited by this paper
  31. Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience · Tauseef Akhtar · 2020 · 13 citations · Cited by this paper
  32. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database · Xiao Chen · 2021 · 11 citations · Cited by this paper
  33. The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies · Alexa E. Schmitz · 2025 · 11 citations · Cited by this paper
  34. Idelalisib ( PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation‐wide real‐world report on consecutively identified patients · Agnes Mattsson · 2023 · 8 citations · Cited by this paper
  35. The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival · Alexey Valeryevich Danilov · 2024 · 8 citations · Cited by this paper
  36. Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media · Cristina Micale · 2023 · 6 citations · Cited by this paper
  37. Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database · Shuai Zhao · 2025 · 6 citations · Cited by this paper
  38. Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen · Peter N. Morcos · 2024 · 5 citations · Cited by this paper
  39. USP10/GSK3β-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer · Nishi Kumari · 2025 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)